Early results show antibody fragment beneficial for wet AMD

November 15, 2003

New York-Treatment with ranibizumab (Lucentis, Genentech) resulted in stable or im-proved vision in 97.5% of patients with wet age-related macular degeneration (AMD) over 6 months, according to the phase Ib/II trial results. Forty-five percent had more than a three-line gain in vision, said Jeffrey S. Heier, MD, a principal investigator in the clinical trial, who reported results at the annual meeting of the American Society of Retina Specialists.